Board of Directors

Sun BioPharma, Inc.

Michael T. Cullen, M.D., MBA

Dr. Cullen has served as Executive Chairman of the board and as a director of our Company since September 2015. He resumed responsibilities as President and Chief Executive Officer of the Company in October 2018. Dr. Cullen brings 30 years of pharmaceutical experience to our Company, including expertise in working with development-stage companies in planning, designing and advancing drug candidates from preclinical through clinical development.

Read more

Art Fratamico, MBA

Mr. Fratamico is a registered pharmacist with over 25 years of experience in the pharmaceutical industry and has been the Chief Business Officer at Galera Therapeutics since January 2017. Prior to joining Galera, Mr. Fratamico served as Chief Business Officer of Vitae Pharmaceuticals until its sale to Allergan.  

Read more

Suzanne Gagnon, M.D.

Dr. Gagnon has served as our Chief Medical Officer and as a director of our Company since September 2015. Dr. Gagnon had previously served as a director of Sun BioPharma Research, Inc. (“SBR”), a former affiliate of the Company, since June 2015 and as its Chief Medical Officer since January 2015. Previously, Dr. Gagnon served as the Lead Clinical Consultant to the Company.

Read more

Jeff Mathiesen

Mr. Mathiesen has served as a director of our Company since September 2015. He has served as Chief Financial Officer of Teewinot Life Sciences, a privately held biopharmaceutical company focused on the biosynthetic production of pure pharmaceutical grade cannabinoids since March 2019. Previously he served as Chief Financial Officer of Gemphire Therapeutics Inc., a publicly traded biopharmaceutical company from September 2015 to September 2018.

Read more

Paul W. Schaffer, PharmD

Mr. Schaffer has served as a director since September 2015. Mr. Schaffer had previously served as a director of SBR since January 2014. Mr. Schaffer graduated from Minnesota Pharmacy School in 1966. He owned and operated a compounding pharmacy, Bloomington Drug, for 42 years. Mr. Schaffer is an experienced biotech investor. Mr. Schaffer brings a wealth of experience in pharmaceutical development and manufacturing to the Board of Directors, as well as knowledge of regulations and issues facing pharmaceutical companies.

Robert Schemel

Mr. Schemel has served as a director since the September 2015. Mr. Schemel had previously served as a director of SBR since March 2012. Mr. Schemel has over 39 years’ experience in the agriculture industry. From 1973-2005, Mr. Schemel owned and operated a farming operation in Kandiyohi County, Minnesota, building a 5,000-acre operation producing corn, soybeans and sugar beets.

Read more

Sun BioPharma Australia, Pty. Ltd.

Michael T. Cullen, M.D., MBA

Dr. Cullen has served as Executive Chairman of the board and as a director of our Company since September 2015. He resumed responsibilities as President and Chief Executive Officer of the Company in October 2018. Dr. Cullen brings 30 years of pharmaceutical experience to our Company, including expertise in working with development-stage companies in planning, designing and advancing drug candidates from preclinical through clinical development.

Read more

David Harle, Ph.D.

Dr Harle has over 25 years of pharmaceutical experience in clinical development, strategic regulatory affairs, pharmacovigilance, QA and business development. He commenced his career at 3M Pharmaceuticals Australia in 1990 and went on to manage the medical department of Knoll Australia. In 1997, he established the Australian office of ICON Clinical Research (a global CRO) and the Asia-Pacific regional office located in Singapore in 1999…

Read more